On October 19, 2026, the clinical trial registry listed a status update for a study involving cagrilintide as part of CagriSema. The trial, titled "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both," is registered as NCT06534411. This is a Phase 3 study. Its current status is listed as completed. The study was designed to compare CagriSema, which includes cagrilintide, against tirzepatide in people with type 2 diabetes who were being treated with metformin, an SGLT2 inhibitor, or both. The registry entry does not include specific outcome data, efficacy results, or safety findings in this update. Cagrilintide remains classified as unapproved and is currently in a research status, not approved for general clinical use. This update reflects only the completion status of the trial as recorded in the registry. No numerical results, conclusions, or comparative performance details were provided as part of this status update. For more background on this compound, readers can consult the compound overview.
CagriSema Phase 3 Trial vs Tirzepatide in Type 2 Diabetes Completed
See the full cagrilintide overview
Source: https://clinicaltrials.gov/study/NCT06534411